Kobayashi Pharmaceutical in $3.2 Billion Buyout Talks After Scandal
Private equity investors are considering a buyout offer for the Japanese firm amid a supplement contamination scandal.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
2 publishers have covered this in 3 articles since 24 Sept 2026. Bloomberg Markets published first, on 24 September at 08:49 UTC; Latest articles followed 3h 28m later. The most recent article, from Latest articles, appeared on 25 September at 02:24 UTC.
Outlets reporting it: Bloomberg Markets (major outlet), Latest articles.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Kobayashi Pharmaceutical Co.